CN111000894A - Application of compound red sage root preparation in treating metabolic syndrome - Google Patents
Application of compound red sage root preparation in treating metabolic syndrome Download PDFInfo
- Publication number
- CN111000894A CN111000894A CN201911374874.2A CN201911374874A CN111000894A CN 111000894 A CN111000894 A CN 111000894A CN 201911374874 A CN201911374874 A CN 201911374874A CN 111000894 A CN111000894 A CN 111000894A
- Authority
- CN
- China
- Prior art keywords
- parts
- salvia miltiorrhiza
- compound
- red sage
- sage root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a new application of compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, wherein the compound salvia miltiorrhiza comprises the following components in parts by weight: 225-675 parts of salvia miltiorrhiza, 70-1100 parts of pseudo-ginseng and 4-12 parts of borneol. The compound red sage root of the invention contains red sage root, notoginseng and borneol with specific content range, and the three components are combined according to proper amount, thereby having good treatment effect on metabolic syndrome and providing a new traditional Chinese medicine selection for the treatment of metabolic syndrome.
Description
Technical Field
The invention relates to a new application of a compound salvia miltiorrhiza preparation, in particular to a new application of a compound salvia miltiorrhiza preparation in treating metabolic syndrome.
Background
① various metabolic disorders are integrated into one body, including obesity, hyperglycemia, hypertension, dyslipidemia, high blood viscosity, hyperuricemia, high fatty liver incidence and hyperinsulinemia, which are pathological bases of cardiovascular and cerebrovascular diseases and diabetes mellitus, it can be seen that diabetes mellitus is not an isolated disease but one of the components of the metabolic syndrome, ② has a common pathological base, and at present, the common cause of the metabolic disorders is obesity, especially insulin resistance and hyperinsulinemia caused by central obesity, ③ can cause various disease increases, such as hypertension, coronary heart disease, cerebral apoplexy, even some cancers, including breast cancer, endometrial cancer, prostate cancer related to sex hormone, pancreatic cancer, liver and gall cancer, colon cancer and the like of the digestive system, ④ has a common prevention and treatment measure, and is beneficial to preventing and treating other metabolic disorders.
The etiology of the metabolic syndrome is not clear, and the metabolic syndrome is considered to be the result of interaction of multiple genes and multiple environments at present and has close relation with heredity, immunity and the like. The disease is influenced by various environmental factors, is mainly expressed in a high-fat and high-carbohydrate dietary structure, increases the occurrence of insulin resistance, and causes the occurrence and development of metabolic syndrome due to low labor intensity and small amount of exercise. The metabolic syndrome is clinically mainly manifested by abdominal obesity or overweight, abnormal lipid metabolism, hypertension, diabetes and the like.
The treatment of metabolic syndrome starts mainly from three aspects, the first is weight loss, generally through the regulation of dietary structure and appropriate exercise; secondly, the insulin resistance is reduced, and besides weight loss and exercise, metformin and insulin sensitizing drugs are generally taken; thirdly, in order to improve the blood lipid disorder, lipid-regulating treatment is an important mode in metabolic syndrome, and common lipid-regulating drugs include fibrates and statins. At present, the treatment of the metabolic syndrome usually takes weight reduction, exercise and western medicine treatment as main treatment, and the traditional Chinese medicine for treating the metabolic syndrome is relatively few in selection.
Disclosure of Invention
The invention aims to solve the defects of the prior art and provides a new application of a compound salvia miltiorrhiza preparation in treating metabolic syndrome.
In order to achieve the purpose, the invention adopts the technical scheme that: the application of compound salvia miltiorrhiza in preparing the medicine for treating the metabolic syndrome comprises the following components in parts by weight: 225-675 parts of salvia miltiorrhiza, 70-1100 parts of pseudo-ginseng and 4-12 parts of borneol.
Salvia miltiorrhiza, which is the dried root and rhizome of Salvia milithiorrhiza bge, has effects of promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness, cooling blood, and resolving carbuncle. Can be used for treating thoracic obstruction, cardialgia, abdominal pain, hypochondriac pain, abdominal mass, pain due to arthralgia, vexation, insomnia, menoxenia, dysmenorrhea, amenorrhea, and pyocutaneous disease with swelling and pain. Notoginseng, the dry root and rhizome of panax notoginseng (panax notoginseng) f.h.chen of the family araliaceae, is warm in nature, sweet in taste and slightly bitter, has significant effects of removing blood stasis, stopping bleeding, reducing swelling and relieving pain, and is mainly used for treating hemoptysis, hematemesis, epistaxis, hematochezia, metrorrhagia, traumatic hemorrhage, thoracico-abdominal pain and traumatic swelling and pain. Borneol is white crystalline powder or flaky crystal prepared by extracting and processing fresh branches and leaves of Presl of Cinnamomum camphora (L.) of Lauraceae, and has fragrant smell, pungent taste, cool taste, volatility, strong smoke when ignited, and yellow flame. It has effects of inducing resuscitation, clearing heat away and relieving pain, and can be used for treating fever unconsciousness, convulsion, apoplexy, phlegm syncope, qi stagnation, syncope, coma, thoracic obstruction, cardiodynia, conjunctival congestion, aphtha, sore throat, and purulence in ear canal. The inventor of the application finds that the salvia miltiorrhiza, the panax notoginseng and the borneol are combined according to a specific proportion range to have a good treatment effect on metabolic syndrome under the combined action of the salvia miltiorrhiza, the panax notoginseng and the borneol, can prepare a medicament for treating the metabolic syndrome by combining the three components with a pharmaceutically acceptable carrier after compounding, and provides a new medicament choice for treating the metabolic syndrome.
As a preferred embodiment of the application of the compound salvia miltiorrhiza in preparing the medicament for treating the metabolic syndrome, the compound salvia miltiorrhiza comprises the following components in parts by weight: 300-600 parts of salvia miltiorrhiza, 150-700 parts of pseudo-ginseng and 5-11 parts of borneol.
As a preferred embodiment of the application of the compound salvia miltiorrhiza in preparing the medicament for treating the metabolic syndrome, the compound salvia miltiorrhiza comprises the following components in parts by weight: 350 parts of salvia miltiorrhiza, 150 parts of pseudo-ginseng and 6 parts of borneol.
As a preferred embodiment of the application of the compound salvia miltiorrhiza in preparing the medicament for treating the metabolic syndrome, the compound salvia miltiorrhiza comprises the following components in parts by weight: 450 parts of salvia miltiorrhiza, 141 parts of pseudo-ginseng and 8 parts of borneol.
As a preferred embodiment of the application of the compound salvia miltiorrhiza in preparing the medicament for treating the metabolic syndrome, the compound salvia miltiorrhiza comprises the following components in parts by weight: 500 parts of salvia miltiorrhiza, 300 parts of pseudo-ginseng and 9 parts of borneol.
As a preferred embodiment of the application of the compound salvia miltiorrhiza in preparing the medicament for treating the metabolic syndrome, the compound salvia miltiorrhiza comprises the following components in parts by weight: 550 parts of salvia miltiorrhiza, 210 parts of pseudo-ginseng and 8 parts of borneol.
As a preferred embodiment of the application of the compound salvia miltiorrhiza in preparing the medicine for treating the metabolic syndrome, the medicine is an oral preparation. As a more preferable embodiment of the application of the compound salvia miltiorrhiza in preparing the medicine for treating the metabolic syndrome, the medicine is a tablet, a capsule, a soft capsule, a dispersible tablet, an orally disintegrating tablet, an effervescent tablet or a pellet.
In the compound red sage root, red sage root is extracted to obtain red sage root extract, pseudo-ginseng and borneol are respectively crushed to obtain fine powder, the obtained pseudo-ginseng fine powder and borneol fine powder are uniformly mixed with the red sage root extract, and the obtained compound red sage root is combined with other pharmaceutically acceptable carriers to prepare the medicine. As a preferred embodiment of the application of the compound salvia miltiorrhiza in the preparation of the medicine for treating the metabolic syndrome, the compound salvia miltiorrhiza accounts for 20-85% of the medicine by mass. As a more preferable embodiment of the application of the compound salvia miltiorrhiza in the preparation of the medicine for treating the metabolic syndrome, the compound salvia miltiorrhiza accounts for 80 percent of the medicine by mass.
The compound red sage root of the invention contains red sage root, notoginseng and borneol with specific content range, and the three components are combined according to proper amount, thus being capable of being used for treating metabolic syndrome. After the red sage root, the pseudo-ginseng and the borneol are compounded, the medicine with different dosage forms can be prepared by combining with a pharmaceutically acceptable carrier, is used for treating metabolic syndrome, and provides a new traditional Chinese medicine choice for treating metabolic syndrome.
Detailed Description
In order to better illustrate the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 300 parts of salvia miltiorrhiza, 340 parts of pseudo-ginseng and 12 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 2
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 350 parts of salvia miltiorrhiza, 150 parts of pseudo-ginseng and 6 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 3
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 450 parts of salvia miltiorrhiza, 141 parts of pseudo-ginseng and 8 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 4
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 500 parts of salvia miltiorrhiza, 300 parts of pseudo-ginseng and 9 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 5
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 550 parts of salvia miltiorrhiza, 210 parts of pseudo-ginseng and 8 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 6
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 600 parts of salvia miltiorrhiza, 450 parts of pseudo-ginseng and 11 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 7
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 225 parts of salvia miltiorrhiza, 70 parts of pseudo-ginseng and 4 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 8
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 675 parts of salvia miltiorrhiza, 1100 parts of pseudo-ginseng and 10 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 9
In an embodiment of an application of the compound salvia miltiorrhiza in preparing a medicament for treating metabolic syndrome, the compound salvia miltiorrhiza in the embodiment comprises the following components in parts by weight: 625 parts of salvia miltiorrhiza, 800 parts of pseudo-ginseng and 5 parts of borneol.
In the compound salvia miltiorrhiza in the embodiment, salvia miltiorrhiza is extracted to obtain salvia miltiorrhiza extract, panax notoginseng and borneol are respectively crushed to obtain fine powder, the obtained panax notoginseng fine powder and borneol fine powder are uniformly mixed with the salvia miltiorrhiza extract, the obtained compound salvia miltiorrhiza is combined with other pharmaceutically acceptable carriers to prepare an oral preparation, the oral preparation in the embodiment includes but is not limited to tablets, capsules, soft capsules, dispersible tablets, orally disintegrating tablets, effervescent tablets, pellets and the like, the mass percentage content of the compound salvia miltiorrhiza in the oral preparation is generally 20-85%, and the compound salvia miltiorrhiza in the oral preparation is reasonably selected according to specific dosage forms and other conditions in practice.
Example 10
The influence of the compound salvia miltiorrhiza in the invention on the metabolic syndrome rat model
1. Establishment of metabolic syndrome rat model
The method is characterized in that male Wistar rats with the weight of 180-220 g are adopted, animals are firstly screened, and animals to be tested are selected according to the standard that the animals rapidly escape, scream, uprise and wheeze and are not easy to adapt when plantar electric shock and noise stimulation are given for the first time. Rats were individually housed in stimulation cages, first normally housed for one week before the start of stimulation, then stimulation was started, 2 times daily, stimulation intensity: stimulation was continued for about 8 weeks 2h each in the morning and afternoon, while high-fat, high-sugar and high-protein diet was given. And (5) performing a sugar tolerance measurement test after the molding is finished. Oral Glucose Tolerance Test (OGTT): after fasting for 12h, the rats are gavaged with 50% glucose solution at the dose of 2.5g/kg, blood is taken from tail veins to detect the blood sugar value for 2h, the rats with the blood sugar lower than 6.2mmol/L and the rats with the body weight lower than 350g are eliminated, and the rest rats are used as the rats to be tested.
2. Test method
The metabolic syndrome rat model is established according to the method, 100 established metabolic syndrome rats are selected and randomly divided into 10 groups, each group comprises 10 rats, and the 10 groups are respectively a model group and test groups 1-9. The test groups 1 to 9 were fed with the drugs prepared in examples 1 to 9, respectively, at a feed rate of 40 mg/(kg. d), and the model group was fed with the same amount of physiological saline. During the feeding period, each group of rats was still fed high-fat diet, and gavage three times a day for 10 consecutive weeks.
3. Test results
3.1 body weight measurement results
Rats in each group were weighed at 4 weeks, 7 weeks, and 10 weeks after dosing, and the average value was taken for each group after weighing, and the weighing results for each group are shown in table 1.
TABLE 1 mean body weight of rats in each group
As can be seen from the results in Table 1, compared with the model group, the test group can significantly reduce the body weight of rats, which indicates that the compound Salvia miltiorrhiza Bunge can inhibit obesity and achieve the effect of losing weight.
3.2 blood pressure and Heart Rate measurements
After the administration, the systolic pressure, diastolic pressure and heart rate of each group of rats were measured with a rat tail artery noninvasive blood pressure meter, and the test results of each group were averaged and are shown in table 2.
Table 2 blood pressure and heart rate test results for each group of rats
| Group of | Systolic pressure (mmHg) | Diastolic blood pressure (mmHg) | Heart rate (times/min) |
| Model set | 182 | 106 | 394 |
| Test group 1 | 170 | 93 | 387 |
| Test group 2 | 158 | 76 | 389 |
| Test group 3 | 147 | 71 | 390 |
| Test group 4 | 154 | 78 | 384 |
| Test group 5 | 152 | 76 | 379 |
| Test group 6 | 171 | 87 | 383 |
| Test group 7 | 169 | 89 | 390 |
| Test group 8 | 167 | 88 | 392 |
| Test group 9 | 165 | 91 | 387 |
As can be seen from the results in Table 2, the systolic pressure and diastolic pressure of the rats in the experimental group are significantly reduced compared with those in the model group, which indicates that the compound Salvia miltiorrhiza Bunge has good antihypertensive effect.
3.3 sugar tolerance test results
After the administration of each group, the rats were fasted for 8 hours without water prohibition, the tails were cut to take blood, fasting blood glucose was measured by a micro-glucometer, after the measurement, the rats were gavaged with 25% glucose (the amount of glucose was determined by body weight, i.e., 2.5g/kg), after 2 hours the tails were cut again to take blood, postprandial blood glucose was measured by a micro-glucometer, the difference between postprandial blood glucose and fasting blood glucose was calculated, the average value was taken for each group, and the results are shown in table 3.
Table 3 results of glucose tolerance test of each group of rats
| Group of | Fasting blood sugar | Postprandial blood glucose | Difference value |
| Model set | 5.83 | 9.02 | 3.19 |
| Test group 1 | 5.81 | 7.34 | 1.53 |
| Test group 2 | 5.84 | 6.85 | 1.01 |
| Test group 3 | 5.79 | 6.43 | 0.64 |
| Test group 4 | 5.82 | 6.51 | 0.69 |
| Test group 5 | 5.86 | 6.49 | 0.63 |
| Test group 6 | 5.77 | 6.92 | 1.15 |
| Test group 7 | 5.84 | 6.97 | 1.13 |
| Test group 8 | 5.83 | 7.25 | 1.42 |
| Test group 9 | 5.85 | 7.18 | 1.33 |
As can be seen from the results in Table 3, compared with the model group, the postprandial blood sugar of the rats in the experimental group is remarkably reduced, which indicates that the compound salvia miltiorrhiza has good blood sugar reducing effect.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. The application of the compound salvia miltiorrhiza in preparing the medicine for treating the metabolic syndrome is characterized in that the compound salvia miltiorrhiza comprises the following components in parts by weight: 225-675 parts of salvia miltiorrhiza, 70-1100 parts of pseudo-ginseng and 4-12 parts of borneol.
2. The use of the compound red sage root of claim 1 in the preparation of a medicament for treating metabolic syndrome, wherein the compound red sage root comprises the following components in parts by weight: 300-600 parts of salvia miltiorrhiza, 150-700 parts of pseudo-ginseng and 5-11 parts of borneol.
3. The use of the compound red sage root of claim 1 in the preparation of a medicament for treating metabolic syndrome, wherein the compound red sage root comprises the following components in parts by weight: 350 parts of salvia miltiorrhiza, 150 parts of pseudo-ginseng and 6 parts of borneol.
4. The use of the compound red sage root of claim 1 in the preparation of a medicament for treating metabolic syndrome, wherein the compound red sage root comprises the following components in parts by weight: 450 parts of salvia miltiorrhiza, 141 parts of pseudo-ginseng and 8 parts of borneol.
5. The use of the compound red sage root of claim 1 in the preparation of a medicament for treating metabolic syndrome, wherein the compound red sage root comprises the following components in parts by weight: 500 parts of salvia miltiorrhiza, 300 parts of pseudo-ginseng and 9 parts of borneol.
6. The use of the compound red sage root of claim 1 in the preparation of a medicament for treating metabolic syndrome, wherein the compound red sage root comprises the following components in parts by weight: 550 parts of salvia miltiorrhiza, 210 parts of pseudo-ginseng and 8 parts of borneol.
7. The use of the compound salvia miltiorrhiza bunge in the preparation of a medicament for treating metabolic syndrome according to claim 1, wherein the medicament is an oral preparation.
8. The use of the compound Danshen root of claim 1, in the preparation of a medicament for the treatment of metabolic syndrome, wherein said medicament is in the form of a tablet, a capsule, a soft capsule, a dispersible tablet, an orally disintegrating tablet, an effervescent tablet, or a pellet.
9. The use of the compound red sage root in the preparation of a medicament for treating metabolic syndrome according to claim 1, wherein the red sage root in the compound red sage root is extracted to obtain a red sage root extract, pseudo-ginseng and borneol are respectively crushed to obtain fine powder, the obtained pseudo-ginseng fine powder and borneol fine powder are uniformly mixed with the red sage root extract, the obtained compound red sage root is added into the medicament, and the mass percentage content of the compound red sage root in the medicament is 20-85%.
10. The use of the compound red sage root of claim 9 in the preparation of a medicament for the treatment of metabolic syndrome, wherein the compound red sage root is 80% by weight of the medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911374874.2A CN111000894A (en) | 2019-12-26 | 2019-12-26 | Application of compound red sage root preparation in treating metabolic syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911374874.2A CN111000894A (en) | 2019-12-26 | 2019-12-26 | Application of compound red sage root preparation in treating metabolic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111000894A true CN111000894A (en) | 2020-04-14 |
Family
ID=70118868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911374874.2A Pending CN111000894A (en) | 2019-12-26 | 2019-12-26 | Application of compound red sage root preparation in treating metabolic syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111000894A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111281903A (en) * | 2020-02-27 | 2020-06-16 | 广东罗浮山国药股份有限公司 | Application of Danqi preparation in treating metabolic syndrome |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1337256A (en) * | 2001-09-20 | 2002-02-27 | 复旦大学 | Application of compound Danshen drip pills in preparing medicine for primary hypertension |
| CN1348815A (en) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use |
| CN1470255A (en) * | 2002-07-22 | 2004-01-28 | 王智民 | Preparation extracted from the root of red-rooted solvia and pseudo-ginseng and its compound preparation and medical use |
| CN1660334A (en) * | 2004-12-24 | 2005-08-31 | 康国忠 | Compound preparation of drop pills of red sange root and preparation method |
| CN1785249A (en) * | 2004-12-06 | 2006-06-14 | 天津天士力制药股份有限公司 | A new application of medicinal composition containing salvia miltiorrhiza |
| CN101062093A (en) * | 2007-05-18 | 2007-10-31 | 中国科学院上海药物研究所 | Chinese medicine composition for treating cardiovascular disease and preparing method thereof |
| CN102293891A (en) * | 2011-08-30 | 2011-12-28 | 时秀燕 | Chinese medicine for treating cardiovascular disease and preparation method thereof |
-
2019
- 2019-12-26 CN CN201911374874.2A patent/CN111000894A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1337256A (en) * | 2001-09-20 | 2002-02-27 | 复旦大学 | Application of compound Danshen drip pills in preparing medicine for primary hypertension |
| CN1348815A (en) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use |
| CN1470255A (en) * | 2002-07-22 | 2004-01-28 | 王智民 | Preparation extracted from the root of red-rooted solvia and pseudo-ginseng and its compound preparation and medical use |
| CN1785249A (en) * | 2004-12-06 | 2006-06-14 | 天津天士力制药股份有限公司 | A new application of medicinal composition containing salvia miltiorrhiza |
| CN1660334A (en) * | 2004-12-24 | 2005-08-31 | 康国忠 | Compound preparation of drop pills of red sange root and preparation method |
| CN101062093A (en) * | 2007-05-18 | 2007-10-31 | 中国科学院上海药物研究所 | Chinese medicine composition for treating cardiovascular disease and preparing method thereof |
| CN102293891A (en) * | 2011-08-30 | 2011-12-28 | 时秀燕 | Chinese medicine for treating cardiovascular disease and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 商敏凤: "复方丹参片新剂型研究概况", 《中药材》 * |
| 李倩: "复方丹参滴丸研究进展及临床应用", 《中华中医药杂志》 * |
| 解发良: "服用中成药降脂 要根据症状选药 ", 《老同志之友》 * |
| 陈志春: "复方丹参滴丸――高血压并发症的克星 ", 《老年人》 * |
| 黄兴，等: "复方丹参滴丸的临床研究进展", 《时珍国医国药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111281903A (en) * | 2020-02-27 | 2020-06-16 | 广东罗浮山国药股份有限公司 | Application of Danqi preparation in treating metabolic syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100562327C (en) | A kind of health food for improving sleep and preparation method thereof | |
| CN103298477B (en) | Comprise Lignum Cudraniae tricuspidatae and Semen Coicis for suppressing fat or falling hypoglycemic composition and use thereof | |
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN117899181B (en) | A Chinese medicine composition for preventing and treating sarcopenia and its preparation method and use | |
| CN104825791A (en) | Fatigue-relieving traditional Chinese medicine health product and preparation method thereof | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN101810636A (en) | Application of Chinese yam polysaccharide in preparation of medicine for treating obesity | |
| CN111000894A (en) | Application of compound red sage root preparation in treating metabolic syndrome | |
| CN102727556A (en) | Throat-clearing traditional Chinese medicine buccal tablet and preparation method thereof | |
| CN107551001B (en) | A kind of traditional Chinese medicine compound for preventing and treating alcoholic liver injury and preparation method thereof | |
| CN111281903A (en) | Application of Danqi preparation in treating metabolic syndrome | |
| CN118304364B (en) | Spleen-invigorating qi-tonifying yin-nourishing collaterals-dredging compound traditional Chinese medicine for treating sicca syndrome | |
| CN102188466A (en) | Novel anti-depression compound preparation | |
| CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
| CN102907673B (en) | Health food composition with auxiliary protective function for gastric mucosa and preparation method thereof | |
| CN106943487B (en) | Composition containing rosemary, preparation method and application thereof | |
| CN105055851B (en) | A kind of traditional Chinese medicine composition for treating diabetes, its preparation and application | |
| CN116421675A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and application thereof | |
| CN111568953A (en) | Glossy privet fruit extract for resisting diabetic nephropathy and preparation method and application thereof | |
| CN103933216B (en) | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application | |
| WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof | |
| CN101269152A (en) | Application of wolfberry fruit and black fungus in preparation of anti-fatty liver medicine | |
| CN106491874B (en) | Traditional Chinese medicine composition for inhibiting enterogenic endotoxemia | |
| CN111840351A (en) | A kind of medicine for treating chronic atrophic gastritis and preparation method thereof | |
| CN108498563A (en) | A kind of chitosan composite and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200414 |
|
| RJ01 | Rejection of invention patent application after publication |